The United Kingdom and the United States have announced a landmark commercial pact that will maintain zero tariffs on UK pharmaceutical exports going into the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to raise funding on drugs through the NHS. This commitment guarantees that duties on these key exports will remain at nothing for a timeframe of three years.
This deal follows recent threats to significantly raise import taxes on patented pharmaceutical imports, with figures discussed up to 100%.
"This deal between the UK bolsters the global environment for new treatments and establishes much-needed fairness to American-British pharmaceutical trade," a statement declared.
Commercial Importance
Pharmaceuticals constitute one of the the United Kingdom's most significant export categories to the US, which is by far the biggest market for leading UK drugmakers.
Statistics show that in the year to the end of last September, the UK shipped medicines worth over eleven billion pounds to the US. This amount accounted for 17.4% of British export trade in that span.
"This agreement safeguards employment, stimulates funding and sets the stage for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Specific NHS Changes
The pact entails several notable commitments from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to double total public funding on treatments from 0.3% of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to prevent overspending will be restricted at fifteen percent. Previously, rebates exceeded 20%.
Broader Context
This agreement follows a long-running tension between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
This friction were heightened by claims that American customers were paying a premium for the same drugs than patients in the UK and Europe.
Recently, several major drug company projects in the UK have been delayed or abandoned, while substantial investments have been pledged toward American operations.
One official acknowledged that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the past decade.
